Zacks Investment Research on MSN
SLN stock skyrockets 107% in six months: Here's what you need to know
Shares of Silence Therapeutics SLN have surged 107% over the past six months, driven by investor optimism around the ...
Zacks Investment Research on MSN
Silence Therapeutics (SLN) moves 7.2% higher: Will this strength last?
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 7.2% in the last trading session to close at $10.45. The move was backed by solid volume with far more shares changing hands than in a normal ...
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...
Following discussions over the last weeks, the French State and Eramet have reached an agreement regarding the treatment of SLN's existing debt. This agreement will neutralize SLN's debt impact on the ...
With a view to the signing of the Pacte Nickel (Nickel Pact), Eramet and the French State have reached an agreement to extend the financial guarantees granted to SLN, enabling SLN to continue to run ...
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 5.7% in the last trading session to close at $22.36. The move was backed by solid volume with far more shares changing hands than in a normal ...
Women with endometrial cancer who are found to have lymph-node-positive disease during surgical staging by lymphadenectomy benefit from adjuvant chemotherapy; however, the remaining 78% of women who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results